Skip to main content
Figure 2 | BMC Health Services Research

Figure 2

From: Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China

Figure 2

Cost-effectiveness of rescue therapies for LAM-resistant HBeAg-positive (A) and HBeAg-negative (B) chronic hepatitis B. The x-axis indicates the discounted lifetime quality-adjusted life-years (QALYs) for each therapy, and the y-axis indicates the total discounted lifetime costs (US dollar). The oblique line connects “no treatment” and the most cost-effective therapies; therapies above the straight lines were dominanated. Combination strategy uses LAM and ADV.

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us